Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

AIDS

Volumn 26, Issue 11, 2012, Pages 1371-1385

  McComsey, Grace A ^a   Kitch, Douglas ^b   Daar, Eric S ^c   Tierney, Camlin ^b   Jahed, Nasreen C ^d   Melbourne, Kathleen ^e   Ha, Belinda ^f   Brown, Todd T ^g   Bloom, Anthony ^g   Fedarko, Neal ^g   Sax, Paul E ^h,i  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e GILEAD SCIENCES   (United States)

^f GLAXOSMITHKLINE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

abacavir; C reactive protein; endothelial activation markers; inflammation markers; interleukin 6; TNF alpha

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENINE; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV-1; HUMANS; INFLAMMATION; INTERLEUKIN-6; LAMIVUDINE; MALE; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; RITONAVIR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863723979     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328354f4fb     Document Type: Article

References (46)

1. Aukrust P, Muller F, Lien E, Nordoy I, Liabakk NB, Kvale D, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999; 179:74-82. (Pubitemid 29028341)
2. Henry K, Kitch D, Dube M, Zackin R, Parker RA, Sprecher D, et al. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavirbased regimen: AIDS Clinical Trials Group 5056 s. AIDS 2004; 18:2434-2437. (Pubitemid 40065914)
3. Ross AC, Armentrout R, O'Riordan MA, Storer N, Rizk N, Harrill D, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008; 49:499-506; PMCID: 2778267.
4. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
5. Lundgren J, Neuhaus J, Babiker A, Cooper DA, Duprez D, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients; Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Study Groups. AIDS 2008; 22:F12-F24.
6. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
7. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr 2011; 57:245-253.
8. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-1298.
9. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a populationbased nationwide cohort study. HIV Med 2010; 11:130-136.
10. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426; PMCID: 2688660.
11. Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and longterm results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929-940; PMCID: 3062545.
12. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
13. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-1238.
14. Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25:1993-2004.
15. Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-1665.
16. McComsey G, Smith K, Patel P, Bellos N, Sloan L, Lackey P, et al., editors. Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT study. 16th Conference on Retroviruses and Opportunistic Infections; 2009 February; Montreal, Canada.
17. Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2011; 27:461-468; PMCID: 3083724.
18. Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657-2663.
19. Martinez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca M, et al. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
20. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240; PMCID: 2800041.
21. McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naïve subjects randomized to abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine along with efavirenz or atazanavir/ritonavir: AIDS Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
22. McComsey G, Kitch D, Sax PE, Tebas P, Tierney C, Jahed N, et al. Peripheral and central fat changes in subjects randomized to abacavir/lamivudine or tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz: ACTG study A5224 s. Clin Infect Dis 2011; 53:185-196.
23. Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-2283. (Pubitemid 44789529)
24. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273; PMCID: 2763381.
25. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 2010; 211:492-498.
26. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
27. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011; 217:207-213.
28. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010; 33:2244-2249.
29. Kumar P, De Jesus E, Huhn G, al. E, editors. Abacavir/lamivudine with fosamprenavir/ritonavir or efavirenz in underrepresented, antiretroviral- naïve HIV-infected subjects (SUPPORT): tolerability, safety, and efficacy after 24 weeks. 18th International AIDS Conference; 2010 July 18-23; Vienna, Austria.
30. Reingold J, Wanke C, Kotler D, Lewis C, Tracy R, Heymsfield S, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-148.
31. Buchbinder S, Kratzsch J, Fiedler GM, Yar V, Brugel M, Leichtle A, et al. Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 2008; 68:140-144. (Pubitemid 351481731)
32. Cauci S, Di Santolo M, Culhane JF, Stel G, Gonano F, Guaschino S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 2008; 111:857-864. (Pubitemid 351482617)
33. Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS 2011; 25:1128-1131.
34. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006; 166:64-70. (Pubitemid 43063843)
35. Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 2003; 32:210-214. (Pubitemid 36222724)
36. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511. (Pubitemid 36158056)
37. De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Alvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. AIDS 2010; 24:1259-1266.
38. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101:295-300; PMCID: 508567. (Pubitemid 28067325)
39. Marchetti G, Casana M, Tincati C, Bellistri GM, Monforte A. Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role? Clin Infect Dis 2008; 47:1495-1496.
40. MacLeod I, Rowley C, Essex M, editors. Molecular basis for the immunostimulatory activity of abacavir via TLR-8. The 19th Conference on Retroviruses and Opportunistic Infections; 2012 March 5-8; Seattle, WA.
41. Satchell CS, Cotter AG, O'Connor EF, Peace AJ, Tedesco AF, Clare A, et al. Platelet function and HIV: a case-control study. AIDS 2010; 24:649-657.
42. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011; 11:40.
43. Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, et al. Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor-or protease inhibitor-containing antiretroviral regimen. J Infect Dis 2003; 188:1444-1454. (Pubitemid 37523929)
44. Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A, et al. Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease. Antivir Ther 2007; 12:553-558. (Pubitemid 47041154)
45. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-561.
46. Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, Domingo JC, Mateo MG, Domingo P, et al. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010; 8:545-553.